Coreg CR Related Published Studies
Well-designed clinical trials related to Coreg CR (Carvedilol)
Endothelial function is unaffected by changing between carvedilol and metoprolol in patients with heart failure-a randomized study. [2011.10.15]
Prevention of chemotherapy-induced left ventricular dysfunction with enalapril and carvedilol: rationale and design of the OVERCOME trial. [2011.08]
Comparison of antihypertensive efficacy of carvedilol and nebivolol in mild-to-moderate primary hypertension: a randomized trial. [2011.06]
Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial. [2011.06]
Effects of Beta-Blockade on Exercise Performance at High Altitude: A Randomized, Placebo-Controlled Trial Comparing the Efficacy of Nebivolol versus Carvedilol in Healthy Subjects. [2011.03.11]
Two-year clinical outcome after carvedilol-loaded stent implantation in patients with coronary artery disease. [2011.03]
Comparison of effectiveness of carvedilol versus bisoprolol for prevention of postdischarge atrial fibrillation after coronary artery bypass grafting in patients with heart failure. [2011.01.15]
Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease: a meta-analysis of randomized trials. [2011.01]
The impact of paroxetine coadministration on stereospecific carvedilol pharmacokinetics. [2010.12]
The role of carvedilol in the management of portal hypertension. [2010.08]
Echocardiographic evaluation of children with systemic ventricular dysfunction treated with carvedilol. [2010.08]
[Effects of carvedilol and metoprolol on expression of autoantibodies against cardiac adrenergic receptors in aged patients with chronic heart failure and ventricular arrhythmia]. [2010.07]
Randomised, cross-over, comparative bioavailability trial of matrix type transdermal drug delivery system (TDDS) of carvedilol and hydrochlorothiazide combination in healthy human volunteers: a pilot study. [2010.07]
Metoprolol compared to carvedilol deteriorates insulin-stimulated endothelial function in patients with type 2 diabetes - a randomized study. [2010.05.25]
Effect of carvedilol on coronary flow reserve in patients with hypertensive left-ventricular hypertrophy. [2010.02]
Efficacy of Carvedilol in Patients with Dilated Cardiomyopathy due to
Beta-thalassemia major; a Double-blind Randomized Controlled Trial. [2010]
Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed. [2009.09]
Beta-receptor selectivity of carvedilol and metoprolol succinate in patients with heart failure (SELECT trial): a randomized dose-ranging trial. [2009.08]
Adherence with once daily versus twice daily carvedilol in patients with heart failure: the Compliance And Quality of Life Study Comparing Once-Daily Controlled-Release Carvedilol CR and Twice-Daily Immediate-Release Carvedilol IR in Patients with Heart Failure (CASPER) Trial. [2009.06]
Comparison of carvedilol and metoprolol on serum lipid concentration in diabetic hypertensive patients. [2009.03]
Carvedilol produces sustained long-term benefits: follow-up at 12 years. [2009.01]
The comparative effects of long-term carvedilol versus bisoprolol therapy on QT dispersion in patients with chronic heart failure. [2009]
Levosimendan versus dobutamine in heart failure patients treated chronically with carvedilol. [2008.09]
Bisoprolol vs. carvedilol in elderly patients with heart failure: rationale and design of the CIBIS-ELD trial. [2008.09]
Demographic analyses of the effects of carvedilol vs metoprolol on glycemic control and insulin sensitivity in patients with type 2 diabetes and hypertension in the Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) study. [2008.09]
Nifedipine versus carvedilol in the treatment of de novo arterial hypertension after liver transplantation: results of a controlled clinical trial. [2008.07]
Electrophysiological effects of carvedilol administration in patients with dilated cardiomyopathy. [2008.06]
Comparison of the efficacy of metoprolol and carvedilol for preventing atrial fibrillation after coronary bypass surgery. [2008.05.07]
Population pharmacokinetics and dose simulation of carvedilol in paediatric patients with congestive heart failure. [2008.04]
Effects of carvedilol on left ventricular function and oxidative stress in infants and children with idiopathic dilated cardiomyopathy: a 12-month, two-center, open-label study. [2008.04]
Comparison of the effects of carvedilol and metoprolol on exercise ventilatory efficiency in patients with congestive heart failure. [2008.03]
Safety and efficacy of carvedilol therapy for patients with dilated cardiomyopathy secondary to muscular dystrophy. [2008.03]
The impact of carvedilol on the defibrillation threshold. [2008.01]
Comparative dose titration responses to the introduction of bisoprolol or carvedilol in stable chronic systolic heart failure. [2007.12]
Carvedilol in dogs with dilated cardiomyopathy. [2007.11]
Ethanol does not alter the pharmacokinetic profile of the controlled-release formulation of carvedilol. [2007.11]
Effect of carvedilol and metoprolol on the mode of death in patients with heart failure. [2007.11]
Effects of carvedilol early after myocardial infarction: analysis of the first 30 days in Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN). [2007.10]
Effect of beta-blocker therapy on left atrial function in patients with heart failure: comparison of metoprolol succinate with carvedilol. [2007.10]
Carvedilol for children and adolescents with heart failure: a randomized controlled trial. [2007.09.12]
Optimal beta-blocker for prevention of atrial fibrillation after on-pump coronary artery bypass graft surgery: carvedilol versus metoprolol. [2007.09]
Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET). [2007.08]
Prognostic importance of plasma NT-pro BNP in chronic heart failure in patients treated with a beta-blocker: results from the Carvedilol Or Metoprolol European Trial (COMET) trial. [2007.08]
Lung function with carvedilol and bisoprolol in chronic heart failure: is beta selectivity relevant? [2007.08]
Randomized active-controlled study comparing effects of treatment with carvedilol versus metoprolol in patients with left ventricular dysfunction after acute myocardial infarction. [2007.07]
Effects of long-term treatment with carvedilol on myocardial blood flow in idiopathic dilated cardiomyopathy. [2007.07]
Effects of carvedilol versus metoprolol on endothelial function and oxidative stress in patients with type 2 diabetes mellitus. [2007.07]
Exercise training reduces sympathetic nerve activity in heart failure patients treated with carvedilol. [2007.06]
Achiral-chiral LC/LC-FLD coupling for determination of carvedilol in plasma samples for bioequivalence purposes. [2007.05.01]
Carvedilol Reduces Elevated B-type Natriuretic Peptide in Dialyzed Patients Without Heart Failure: Cardioprotective Effect of the beta-blocker. [2007.04]
A randomized trial of carvedilol after renin-angiotensin system inhibition in chronic Chagas cardiomyopathy. [2007.04]
Evaluation of cardiac sympathetic nerve activity and left ventricular remodelling in patients with dilated cardiomyopathy on the treatment containing carvedilol. [2007.04]
Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET. [2007.03.06]
Beneficial effects of carvedilol as a concomitant therapy to angiotensin-converting enzyme inhibitor in patients with ischemic left ventricular systolic dysfunction. [2007.02]
The antioxidative effects of long-term treatment are more pronounced for carvedilol than for atenolol in post-myocardial infarction patients. [2007.01]
Carvedilol in the treatment of chronic heart failure: lessons from the Carvedilol Or Metoprolol European Trial. [2007]
Protective effects of carvedilol against anthracycline-induced cardiomyopathy. [2006.12.05]
Efficacy of a once-daily formulation of carvedilol for the treatment of hypertension. [2006.12]
Adrenergic blocker carvedilol attenuates the cardiovascular and aversive effects of nicotine in abstinent smokers. [2006.12]
Carvedilol reduces exercise-induced hyperventilation: A benefit in normoxia and a problem with hypoxia. [2006.11]
[The effectiveness of carvedilol in heart failure] [2006.10.08]
Controlled-release carvedilol in the treatment of essential hypertension. [2006.10.02]
Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension. [2006.10.02]
Randomized, double-blind comparison of acute beta1-blockade with 50 mg metoprolol tartrate vs 25 mg carvedilol in normal subjects. [2006.09]
Carvedilol versus Metoprolol for the prevention of atrial fibrillation after off-pump coronary bypass surgery: rationale and design of the Carvedilol or Metoprolol Post-Revascularization Atrial Fibrillation Controlled Trial (COMPACT). [2006.06]
The effect of carvedilol on metabolic parameters in patients with metabolic syndrome. [2006.05]
A comparison of the effects of carvedilol and metoprolol on well-being, morbidity, and mortality (the "patient journey") in patients with heart failure: a report from the Carvedilol Or Metoprolol European Trial (COMET). [2006.04.18]
Rapid titration of carvedilol in patients with congestive heart failure: a randomized trial of automated telemedicine versus frequent outpatient clinic visits. [2006.04]
After myocardial infarction carvedilol improves insulin resistance compared to metoprolol. [2006.02]
The effect of carvedilol on mortality risk in heart failure patients with diabetes: results of a meta-analysis. [2006.02]
Randomized placebo-controlled study on the effects of losartan and carvedilol on albuminuria in renal transplant recipients. [2006.01.15]
Comparison of carvedilol and metoprolol in patients with acute myocardial infarction undergoing primary coronary intervention--the PASSAT Study. [2006.01]
Effects of nebivolol versus carvedilol on left ventricular function in patients with chronic heart failure and reduced left ventricular systolic function. [2006]
Comparing beta-blocking effects of bisoprolol, carvedilol and nebivolol. [2006]
Carvedilol exerts more potent antiadrenergic effect than metoprolol in heart failure. [2005.10]
Different responses to dobutamine in the presence of carvedilol or metoprolol in patients with chronic heart failure. [2003.06]
Well-designed clinical trials possibly related to Coreg CR (Carvedilol)
Influence of global region on outcomes in heart failure beta-blocker trials. [2011.08.23]
Beta-blockade restores muscle sympathetic rhythmicity in human heart failure. [2011.05.25]
Effects of selective and nonselective beta-blockade on 24-h ambulatory blood pressure under hypobaric hypoxia at altitude. [2011.02]
Effects of cAMP and beta-adrenergic receptor antagonists on the function of peripheral T helper lymphocytes in patients with heart failure. [2011]
Importance of blood pressure control in left ventricular mass regression. [2010.11]
Candesartan decreases type III procollagen-N-peptide levels and inflammatory marker levels and maintains sinus rhythm in patients with atrial fibrillation. [2010.05]
Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. [2010.04.27]
Effects of beta-blockers on glucose and lipid metabolism. [2010.03]
[Effect of beta-adrenoblockers on remodeling of myocardium and adhesive function of endothelium in patients with ischemic heart disease, complicated with chronic heart failure and atrial fibrillation] [2010]
Therapeutic window for calcium-channel blockers in the management of dilated cardiomyopathy: a prospective, two-centre study on non-advanced disease. [2010]
Clinical trials update from the European Society of Cardiology heart failure meeting 2009: CHANCE, B-Convinced, CHAT, CIBIS-ELD, and Signal-HF. [2009.08]
A pilot study on the role of autoantibody targeting the beta1-adrenergic receptor in the response to beta-blocker therapy for congestive heart failure. [2009.04]
Changes in platelet size and spleen volume in response to selective and non-selective beta-adrenoceptor blockade in hypertensive patients. [2009.04]
LC-MS/MS assay of quinapril and its metabolite quinaprilat for drug bioequivalence evaluation: prospective, concurrential and retrospective method validation. [2009.04]
Years-needed-to-treat to add 1 year of life: a new metric to estimate treatment effects in randomized trials. [2009.03]
Effect of beta-blockade and ACE inhibition on B-type natriuretic peptides in stable patients with systolic heart failure. [2008.08]
Inpatient initiation of beta-blockade plus nurse management in vulnerable heart failure patients: a randomized study. [2008.05]
A Review of Evidence-Based beta-Blockers in Special Populations With Heart Failure. [2008.03]
Effect of selective and non-selective beta-blockers on body weight, insulin resistance and leptin concentration in chronic heart failure. [2008.01]
Pediatric Heart Failure Therapy with beta-Adrenoceptor Antagonists. [2008]
Lowering blood pressure with beta-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes: results from the GEMINI Trial. [2007.11]
Cardiovascular disease in patients with chronic kidney disease. A clinical review. [2007.09]
The effects of beta-blockers in patients with stable chronic heart failure. Predictors of left ventricular ejection fraction improvement and impact on prognosis. [2007.09]
Does NT-proBNP remain a sensitive biomarker for chronic heart failure after administration of a beta-blocker? [2007.09]
Should beta-blocker therapy be reduced or withdrawn after an episode of decompensated heart failure? Results from COMET. [2007.09]
|
